These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 33580230)

  • 41. Nobel Dreams Come True for Doudna and Charpentier.
    Barrangou R
    CRISPR J; 2020 Oct; 3(5):317-318. PubMed ID: 33095041
    [No Abstract]   [Full Text] [Related]  

  • 42. Rapid and efficient CRISPR-mediated genome editing with cloning-free method.
    Liu W; Zhang Y; Li S; Li Y
    Acta Biochim Biophys Sin (Shanghai); 2018 Nov; 50(11):1173-1175. PubMed ID: 30379982
    [No Abstract]   [Full Text] [Related]  

  • 43. Editor's comment on "CRISPR/Cas9-mediated gene editing in human zygotes using Cas9 protein".
    Hohmann S
    Mol Genet Genomics; 2017 Jun; 292(3):535-536. PubMed ID: 28251316
    [No Abstract]   [Full Text] [Related]  

  • 44. Prime Editing: A Novel Cas9-Reverse Transcriptase Fusion May Revolutionize Genome Editing.
    Flotte TR; Gao G
    Hum Gene Ther; 2019 Dec; 30(12):1445-1446. PubMed ID: 31860398
    [No Abstract]   [Full Text] [Related]  

  • 45. Transient editing catches the eye.
    Nat Biomed Eng; 2021 Feb; 5(2):127. PubMed ID: 33580230
    [No Abstract]   [Full Text] [Related]  

  • 46. Rock paper scissors: CRISPR/Cas9-mediated interference with geminiviruses in plants.
    Yang X; Zhou H; Zhou X
    Sci China Life Sci; 2019 Oct; 62(10):1389-1391. PubMed ID: 31571024
    [No Abstract]   [Full Text] [Related]  

  • 47. CRISPR/Cas9 System and its Research Progress in Gene Therapy.
    Liu W; Yang C; Liu Y; Jiang G
    Anticancer Agents Med Chem; 2019; 19(16):1912-1919. PubMed ID: 31633477
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CRISPR/Cas9-based epigenome editing: An overview of dCas9-based tools with special emphasis on off-target activity.
    Tadić V; Josipović G; Zoldoš V; Vojta A
    Methods; 2019 Jul; 164-165():109-119. PubMed ID: 31071448
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Harnessing CRISPR/Cas9 technology in cardiovascular disease.
    Rezaei H; Khadempar S; Farahani N; Hosseingholi EZ; Hayat SMG; Sathyapalan T; Sahebkar AH
    Trends Cardiovasc Med; 2020 Feb; 30(2):93-101. PubMed ID: 30935726
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sharpening the Scissors: Mechanistic Details of CRISPR/Cas9 Improve Functional Understanding and Inspire Future Research.
    Raper AT; Stephenson AA; Suo Z
    J Am Chem Soc; 2018 Sep; 140(36):11142-11152. PubMed ID: 30160947
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Challenges of in vitro genome editing with CRISPR/Cas9 and possible solutions: A review.
    Ebrahimi V; Hashemi A
    Gene; 2020 Aug; 753():144813. PubMed ID: 32470504
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Genome engineering in ophthalmology: Application of CRISPR/Cas to the treatment of eye disease.
    Hung SSC; McCaughey T; Swann O; Pébay A; Hewitt AW
    Prog Retin Eye Res; 2016 Jul; 53():1-20. PubMed ID: 27181583
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Recent Advances in CRISPR/Cas9-Mediated Genome Editing in
    Muramoto T; Iriki H; Watanabe J; Kawata T
    Cells; 2019 Jan; 8(1):. PubMed ID: 30642074
    [TBL] [Abstract][Full Text] [Related]  

  • 54.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.